ArticleIn vivo (Athens, Greece)
Impact of Intravenous Immunoglobulin on Neuroinflammation Markers in Patients With Electrical Status Epilepticus During Slow Sleep.
Article in In vivo (Athens, Greece). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND/
aimElectrical status epilepticus during slow sleep (ESES) is a rare syndrome that often presents with refractory seizures and cognitive impairment. Immune modulatory drugs may show higher efficacy than anti-seizure drugs (ASD) in ESES. Our study aimed to determine the immune-modulatory treatment-responsive subgroups through assessment of neuroinflammatory mediators. PATIENTS AND
methodsThe study included thirty-five consecutively diagnosed patients with treatment-resistant ESES, all under ASD treatment and the control group comprised 25 individuals diagnosed with primary headache disorders. Serum, peripheral blood and cerebrospinal fluid (CSF) samples were collected before commencement and after the 12-month follow-up of monthly intravenous immunoglobulin (IVIg)+ASD regimen. Serum and/or CSF levels of YKL-40, CXCL13, HMGB1, GFAP and NFL and
resultsSeizures and ESES activity ceased in 20 (57.1%) patients with ESES. Under IVIg+ASD, CSF levels of YKL-40, CXCL13, HMGB1 and GFAP and serum levels of YKL-40 and HMGB1 were significantly reduced, whereas serum CXCL13, CSF NFL, PBMC
conclusionIVIg treatment dampens the neuroinflammatory response and thus immune-modulatory treatment in combination with ASD may contribute to the improvement of ESES symptoms. CXCL13, HMGB1 and IL-1β may serve as markers of immune-modulatory treatment response in ESES.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.